id: stimulant_use_disorder_to_sud_medication_treatment_rate_oud
name: Stimulant Use Disorder â†’ MOUD Treatment Rate for OUD
from_node:
  node_id: stimulant_use_disorder
  node_name: Stimulant Use Disorder
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: MOUD Treatment Rate for OUD
direction: negative
category: behavioral
mechanism_pathway:
- 'Step 1: Co-use of stimulants and opioids creates polysubstance use patterns that complicate treatment
  initiation'
- 'Step 2: Stimulant use may interfere with completing required detoxification or stabilization periods
  before MOUD initiation'
- 'Step 3: Treatment programs may have structural barriers or exclusion criteria for patients with active
  stimulant use'
- 'Step 4: Reduced likelihood of initiating buprenorphine or extended-release naltrexone treatment among
  people with OUD'
evidence:
  quality_rating: B
  n_studies: 2
  primary_citation: R. Cook et al. 2023. "Estimating the impact of stimulant use on initiation of buprenorphine
    and extended-release naltrexone in two clinical trials and real-world populations." https://doi.org/10.1186/s13722-023-00364-3
  supporting_citations:
  - CTN-0051 X:BOT clinical trial (referenced in methods)
  - CTN-0067 CHOICES clinical trial (referenced in methods)
  - National Survey on Drug Use and Health (NSDUH) - population data source
  doi: 10.1186/s13722-023-00364-3
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Stimulant use reduces the likelihood of initiating medications for opioid use disorder (MOUD)
  including buprenorphine and extended-release naltrexone by 32% in clinical trial populations. This barrier
  to treatment is particularly pronounced for XR-NTX initiation and among rural populations who inject
  drugs.
quantitative_effects:
  effect_size:
    value: 0.68
    type: hazard_ratio
    ci_lower: 0.49
    ci_upper: 0.94
  p_value: 0.019
  sample_size: 673
spatial_variation:
  varies_by_geography: true
  variation_notes: Effects were more pronounced in rural populations injecting drugs (39% reduction, aHR=0.61)
    compared to housed adults needing treatment (25% reduction, aHR=0.75) or adults entering OUD treatment
    (28% reduction, aHR=0.72)
moderators:
- name: rural_residence
  direction: strengthens
  strength: moderate
  description: Rural people injecting drugs showed stronger negative association between stimulant use
    and MOUD initiation (39% reduction vs 32% in RCTs)
- name: medication_type
  direction: strengthens
  strength: strong
  description: Stimulant use had larger negative impact on XR-NTX initiation compared to buprenorphine,
    especially in rural populations (76% reduction for XR-NTX)
structural_competency:
  equity_implications: This mechanism highlights structural barriers to OUD treatment for people with
    polysubstance use. Rather than blaming individuals for stimulant use, the finding points to treatment
    system limitations that fail to accommodate the complex needs of people with co-occurring stimulant
    and opioid use disorders. Rural populations face compounded structural disadvantages including limited
    MOUD access and higher barriers to XR-NTX initiation. The finding calls for interventions addressing
    stimulant use among OUD patients and expanded treatment capacity in underserved areas.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.224618'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
